BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 25602965)

  • 1. ACTN4 copy number increase as a predictive biomarker for chemoradiotherapy of locally advanced pancreatic cancer.
    Watanabe T; Ueno H; Watabe Y; Hiraoka N; Morizane C; Itami J; Okusaka T; Miura N; Kakizaki T; Kakuya T; Kamita M; Tsuchida A; Nagakawa Y; Wilber H; Yamada T; Honda K
    Br J Cancer; 2015 Feb; 112(4):704-13. PubMed ID: 25602965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurement of copy number of ACTN4 to optimize the therapeutic strategy for locally advanced pancreatic cancer.
    Shoji H; Miura N; Ueno H; Honda K
    Pancreatology; 2018 Sep; 18(6):624-629. PubMed ID: 29921500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study.
    Choi Y; Oh DY; Kim K; Chie EK; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Ha SW; Bang YJ
    Cancer Res Treat; 2016 Jul; 48(3):1045-55. PubMed ID: 26511805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct outcome of stage I lung adenocarcinoma with ACTN4 cell motility gene amplification.
    Noro R; Honda K; Tsuta K; Ishii G; Maeshima AM; Miura N; Furuta K; Shibata T; Tsuda H; Ochiai A; Sakuma T; Nishijima N; Gemma A; Asamura H; Nagai K; Yamada T
    Ann Oncol; 2013 Oct; 24(10):2594-2600. PubMed ID: 23899839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Copy number increase of ACTN4 is a prognostic indicator in salivary gland carcinoma.
    Watabe Y; Mori T; Yoshimoto S; Nomura T; Shibahara T; Yamada T; Honda K
    Cancer Med; 2014 Jun; 3(3):613-22. PubMed ID: 24574362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of gene amplification of ACTN4 in stage I and II oral tongue cancer.
    Kakuya T; Mori T; Yoshimoto S; Watabe Y; Miura N; Shoji H; Onidani K; Shibahara T; Honda K
    Int J Oral Maxillofac Surg; 2017 Aug; 46(8):968-976. PubMed ID: 28385383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paraneoplastic thrombocytosis independently predicts poor prognosis in patients with locally advanced pancreatic cancer.
    Chadha AS; Kocak-Uzel E; Das P; Minsky BD; Delclos ME; Mahmood U; Guha S; Ahmad M; Varadhachary GR; Javle M; Katz MH; Fleming JB; Wolff RA; Crane CH; Krishnan S
    Acta Oncol; 2015 Jul; 54(7):971-8. PubMed ID: 25608822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer.
    Torgeson A; Lloyd S; Boothe D; Tao R; Whisenant J; Garrido-Laguna I; Cannon GM
    Cancer; 2017 Oct; 123(19):3816-3824. PubMed ID: 28621885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.
    Mellon EA; Hoffe SE; Springett GM; Frakes JM; Strom TJ; Hodul PJ; Malafa MP; Chuong MD; Shridhar R
    Acta Oncol; 2015 Jul; 54(7):979-85. PubMed ID: 25734581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha-actinin-4 (ACTN4) gene amplification is a predictive biomarker for adjuvant chemotherapy with tegafur/uracil in stage I lung adenocarcinomas.
    Noro R; Honda K; Nagashima K; Motoi N; Kunugi S; Matsubayashi J; Takeuchi S; Shiraishi H; Okano T; Kashiro A; Meng X; Yoshida Y; Watanabe S; Usuda J; Inoue T; Wilber H; Ikeda N; Seike M; Gemma A; Kubota K
    Cancer Sci; 2022 Mar; 113(3):1002-1009. PubMed ID: 34845792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy and intensity-modulated radiation therapy for locally advanced pancreatic cancer achieves a high rate of R0 resection.
    Huguet F; Hajj C; Winston CB; Shi W; Zhang Z; Wu AJ; O'Reilly EM; Reidy DL; Allen P; Goodman KA
    Acta Oncol; 2017 Mar; 56(3):384-390. PubMed ID: 27796165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Actinin-4 gene amplification in ovarian cancer: a candidate oncogene associated with poor patient prognosis and tumor chemoresistance.
    Yamamoto S; Tsuda H; Honda K; Onozato K; Takano M; Tamai S; Imoto I; Inazawa J; Yamada T; Matsubara O
    Mod Pathol; 2009 Apr; 22(4):499-507. PubMed ID: 19151661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy with or Without Definitive Radiation Therapy in Inoperable Pancreatic Cancer.
    Zhong J; Switchenko J; Behera M; Kooby D; Maithel SK; McDonald MW; Lin JY; Cassidy RJ; El-Rayes B; Landry J; Patel PR
    Ann Surg Oncol; 2018 Apr; 25(4):1026-1033. PubMed ID: 29327180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretreatment C-reactive protein level predicts outcome and patterns of failure after chemoradiotherapy for locally advanced pancreatic cancer.
    Kishi T; Nakamura A; Itasaka S; Shibuya K; Matsumoto S; Kanai M; Kodama Y; Takaori K; Mizowaki T; Hiraoka M
    Pancreatology; 2015; 15(6):694-700. PubMed ID: 26601881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A nomogram for predicting survival of patients with locally advanced pancreatic cancer treated with chemoradiotherapy.
    Choi SH; Park SW; Seong J
    Radiother Oncol; 2018 Nov; 129(2):340-346. PubMed ID: 30177371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of ACTN4 gene copy number alteration in hormone receptor-positive, HER2-negative, node-negative invasive breast carcinoma.
    Sugano T; Yoshida M; Masuda M; Ono M; Tamura K; Kinoshita T; Tsuda H; Honda K; Gemma A; Yamada T
    Br J Cancer; 2020 Jun; 122(12):1811-1817. PubMed ID: 32265507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum ferritin predicted prognosis in patients with locally advanced pancreatic cancer.
    Wang SL; Cao S; Wu R; Chi F; Tang MY; Jin XY; Chen XD
    Future Oncol; 2015; 11(21):2905-10. PubMed ID: 26436474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies.
    Huguet F; André T; Hammel P; Artru P; Balosso J; Selle F; Deniaud-Alexandre E; Ruszniewski P; Touboul E; Labianca R; de Gramont A; Louvet C
    J Clin Oncol; 2007 Jan; 25(3):326-31. PubMed ID: 17235048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy.
    Martin RC; Kwon D; Chalikonda S; Sellers M; Kotz E; Scoggins C; McMasters KM; Watkins K
    Ann Surg; 2015 Sep; 262(3):486-94; discussion 492-4. PubMed ID: 26258317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of radiotherapy to adjuvant chemotherapy is associated with improved overall survival in resected pancreatic adenocarcinoma: An analysis of the National Cancer Data Base.
    Rutter CE; Park HS; Corso CD; Lester-Coll NH; Mancini BR; Yeboa DN; Johung KL
    Cancer; 2015 Dec; 121(23):4141-9. PubMed ID: 26280559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.